

Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc.
7-23-20

Astellas Pharma US, Inc. (Astellas) has recalculated 340B ceiling prices for Q3 2019 for the products listed below.

Astellas has used chargeback data to identify covered entities that may be eligible for potential payment based on recalculated 340B ceiling prices, and to identify potential payment amounts to affected 340B covered entities. For covered entities that may be owed \$1,000 or more, Astellas will be working with Apexus, LLC (Apexus), the 340B Prime Vendor, to issue refunds. Refunds will be issued either to a covered entity's validated wholesaler pharmacy account when one can be identified, or directly to a covered entity if such covered entity's wholesaler account cannot be identified. For covered entities that may be owed less than \$1,000, and for covered entities that have questions regarding this 340B recalculation and refund process, please send an email to Dawn Powell at Dawn.Powell@astellas.com. Astellas is not seeking reimbursement or repayment where covered entities paid a lower price than the recalculated Q3 2019 340B ceiling prices.

Astellas has asked the Office of Pharmacy Affairs (OPA) to post this Notice on OPA's public website to ensure transparency by providing access to information about Astellas's recalculation affecting certain 340B covered entities for the impacted products.

NDC	Product Description
00469-2601-30	Myrbetriq ER 25MG Tablet
00469-2601-90	Myrbetriq ER 25MG Tablet
00469-2602-30	Myrbetriq ER 50MG Tablet
00469-2602-90	Mybretriq ER 50MG Tablet